You are here
- Home
Key Nexium studies
In keeping with AstraZeneca’s commitment to providing healthcare professionals and patients with relevant information to enable them to make the best decisions about treatment, clinical data for Nexium are carried on AstraZenecaClinicalTrials.com. This website contains summaries of results of completed clinical trials sponsored by AstraZeneca regarding our currently marketed medicines and for any of our medicines in development that has been discontinued.
The following studies represent a sample of the key clinical data that support the Nexium indication. Before prescribing any AZ products, Healthcare Professionals should view their country specific information.
- EAZEE study revealed Nexium was significantly more effective in healing of esophagitis than lansoprazole, and produced significantly higher healing rates for all patients with esophagitis, even those with more severe damage
Download the EAZEE study in pdf format
- METROPOLE study revealed that Nexium achieves significantly higher remission rates than lansoprazole during six months maintenance therapy in patients with healed RE[i]
Download the METROLPOLE study in pdf format
- A 2003 five-way crossover study demonstrates that Nexium suppresses stomach acid more effectively and for longer periods of time than any of the other branded PPIs
- EXPO study demonstrated that Nexium achieved significantly higher healing rates after four weeks (80.9 per cent versus 74.5 per cent) and provides faster symptom relief in patients with RE than pantoprazole
Download the EXPO study in pdf format
- Results from the ASTERIX study showed that taking Nexium in addition to low-dose aspirin therapy, significantly reduced incidence of peptic ulcers (gastric and duodenal) in patients at risk - treatment with Nexium resulted in 70 per cent reduction in ulcer development compared to placebo
- The Esomeprazole Peptic Ulcer Bleed Study demonstrated that a high-dose of esomeprazole delivered intravenously significantly reduces peptic ulcer re-bleeding in high-risk patients
Download the ESOMEPRAZOLE peptic ulcer bleed study in pdf format
- A comparative six-way crossover study demonstrated that Nexium provides acid control significantly superior to that of pantoprazole in patients with GERD across a range of doses, including the standard dose of each medication.
Download the Nexium GERD study in pdf format
- OBERON study presented at DDW 2009 demonstrated that esomeprazole significantly reduces the occurrence of gastric/duodenal ulcers and upper GI symptoms in high risk cardiovascular (CV) patients on low dose aspirin
References
- Lauritsen K et al. Esomeprazole 20mg and lansoprazole 15mg in maintaining healed reflux esophagitis. Metropole Study Results. Aliment Pharmacol Ther 2003; 17: 333-41
